Dr. Laurent Chaloin has held a Research Director position at CNRS in Montpellier, France, since 2018. He obtained his PhD in 1998 on the development of carrier peptides for the intracellular delivery of therapeutic drugs, followed by two post-doctoral positions at the Max-Planck-Institute in Dortmund (focusing on HIV-1 reverse transcriptase) and in France (Drug delivery) until 2002 where he obtained a permanent position at CNRS as a research scientist. His main research contributions have been the discovery of new selective and potent inhibitors of various enzymes (such as nucleotidases and aminoglycoside phosphotransferases) or antiviral drugs against HIV-1. His main focus is the fight against viral and bacterial pathogens, and his topics have included antibiotic resistance with the repurposing of approved drugs and the development of innovative therapeutic agents that act as antiviral drugs or are able to reactivate latently infected cells. His current projects are now focused on the development of novel therapeutics for the treatment of viral infections including dengue, chikungunya, HTLV-1, HIV-1 and SARS-CoV-2 viruses, by targeting a unique cellular protein.